A new drug targeted at preventing the recurrence of liver cancer after it is treated surgically is expected to receive approval in most Asian countries by 2015, according to the company authorized to develop, produce and market the drug.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Typhoon, rain cause over NT$2.6 billion in agricultural losses in Taiwan
07/14/2025 10:33 PM - Society
Warmth in the dark: Anonymous man shows respect to Taipower workers
07/14/2025 10:28 PM - Sports
Taiwan billiards star Chang Jung-lin dies suddenly aged 40
07/14/2025 09:54 PM - Business
Taiwan's stabilization fund to continue stock market intervention
07/14/2025 09:18 PM - Politics
Urban resilience drills begin Tuesday
07/14/2025 09:08 PM